Jeffrey William Henderson Sells 5,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the sale, the director now owns 33,611 shares in the company, valued at $1,972,629.59. The trade was a 12.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.30, for a total value of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $50.01, for a total value of $500,100.00.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $58.14 on Wednesday. The stock has a fifty day moving average price of $54.74 and a two-hundred day moving average price of $54.72. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The firm has a market cap of $7.16 billion, a P/E ratio of 16.95, a PEG ratio of 0.42 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on HALO shares. Benchmark restated a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. HC Wainwright raised their target price on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Finally, Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $62.78.

Institutional Investors Weigh In On Halozyme Therapeutics

Several large investors have recently modified their holdings of HALO. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Halozyme Therapeutics by 20.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,582 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 782 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in shares of Halozyme Therapeutics by 7.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 14,838 shares of the biopharmaceutical company’s stock worth $849,000 after acquiring an additional 995 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 32.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,495 shares of the biopharmaceutical company’s stock worth $315,000 after acquiring an additional 1,358 shares in the last quarter. New York State Teachers Retirement System boosted its stake in shares of Halozyme Therapeutics by 12.8% during the 3rd quarter. New York State Teachers Retirement System now owns 127,327 shares of the biopharmaceutical company’s stock worth $7,288,000 after acquiring an additional 14,489 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 173.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 1,028 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.